JP2012529444A - ペプチドギャップ結合調節因子として作用する化合物及びその使用 - Google Patents

ペプチドギャップ結合調節因子として作用する化合物及びその使用 Download PDF

Info

Publication number
JP2012529444A
JP2012529444A JP2012514348A JP2012514348A JP2012529444A JP 2012529444 A JP2012529444 A JP 2012529444A JP 2012514348 A JP2012514348 A JP 2012514348A JP 2012514348 A JP2012514348 A JP 2012514348A JP 2012529444 A JP2012529444 A JP 2012529444A
Authority
JP
Japan
Prior art keywords
arg
compound
peptide
substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529444A5 (cg-RX-API-DMAC7.html
Inventor
デルマー マリオ
エム．タフェット スティーブン
クームス ワンダ
バーマ バンダナ
デュー ラーセン ブヤルネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Research Foundation of the State University of New York
Original Assignee
University of Michigan System
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, Research Foundation of the State University of New York filed Critical University of Michigan System
Publication of JP2012529444A publication Critical patent/JP2012529444A/ja
Publication of JP2012529444A5 publication Critical patent/JP2012529444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
JP2012514348A 2009-06-12 2010-06-11 ペプチドギャップ結合調節因子として作用する化合物及びその使用 Pending JP2012529444A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09007772A EP2260859A1 (en) 2009-06-12 2009-06-12 Compounds acting as peptide gap junction modulators and their uses
EP09007772.8 2009-06-12
US18783909P 2009-06-17 2009-06-17
US61/187,839 2009-06-17
PCT/DK2010/000092 WO2010142293A1 (en) 2009-06-12 2010-06-11 Compounds acting as peptide gap junction modulators, and uses thereof

Publications (2)

Publication Number Publication Date
JP2012529444A true JP2012529444A (ja) 2012-11-22
JP2012529444A5 JP2012529444A5 (cg-RX-API-DMAC7.html) 2013-08-01

Family

ID=41217722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514348A Pending JP2012529444A (ja) 2009-06-12 2010-06-11 ペプチドギャップ結合調節因子として作用する化合物及びその使用

Country Status (4)

Country Link
US (1) US20120264693A1 (cg-RX-API-DMAC7.html)
EP (2) EP2260859A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012529444A (cg-RX-API-DMAC7.html)
WO (1) WO2010142293A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512139D0 (en) * 2015-07-10 2015-08-19 Zealand Pharma As Methods of treatment
US20190054184A1 (en) * 2016-02-12 2019-02-21 The General Hospital Corporation Targeting Macrophages to Modulate Electrical Conduction in the Heart
EP4291178A1 (en) * 2021-02-10 2023-12-20 Breye Therapeutics ApS Danegaptide for use in the treatment or prevention of a kidney disease
GB202310195D0 (en) * 2023-07-03 2023-08-16 Hastings Nataly Method for mitigating symptoms of neurological condition and a system therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528826A (ja) * 2000-02-23 2003-09-30 ジーランド・ファーマ・ア／エス 新規な抗不整脈性ペプチド
WO2007084895A2 (en) * 2006-01-13 2007-07-26 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
WO2009012224A2 (en) * 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
WO2009010733A2 (en) * 2007-07-15 2009-01-22 Zealand Pharma A/S Peptide gap junction modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528826A (ja) * 2000-02-23 2003-09-30 ジーランド・ファーマ・ア／エス 新規な抗不整脈性ペプチド
WO2007084895A2 (en) * 2006-01-13 2007-07-26 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
WO2009012224A2 (en) * 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
WO2009010733A2 (en) * 2007-07-15 2009-01-22 Zealand Pharma A/S Peptide gap junction modulators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6014043625; Ｃｉｒｃ．　Ｒｅｓ．，　２００６，　９８（１１），　ｐｐ．１３６５-１３７２ *
JPN6014043627; Ｃｉｒｃ．　Ｒｅｓ．，　２００８，　１０３（５），　ｐｐ．５１９-５２６ *
JPN6014043629; Ｈｅｌｖ．　Ｃｈｉｍ．　Ａｃｔａ，　１９９８，　８１（９），　ｐｐ．１７２６-１７３８ *
JPN6014043632; Ｊ．　Ａｍ．　Ｃｈｅｍ．　Ｓｏｃ．，　２００６，　１２８（２４），　ｐｐ．７９１６-７９２８ *
JPN6014043634; Ｔｅｔｒａｈｅｄ．　Ｌｅｔｔ．，　１９９２，　３３（３２），　ｐｐ．４５５７-４５６０ *

Also Published As

Publication number Publication date
WO2010142293A1 (en) 2010-12-16
EP2260859A1 (en) 2010-12-15
US20120264693A1 (en) 2012-10-18
EP2440229A1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
US9234036B2 (en) Modulation of activity of proneurotrophins
US8815808B2 (en) Modulation of activity of neurotrophins
US8106020B2 (en) Calcium receptor activator
BRPI0715407A2 (pt) peptÍdeos e seus derivados funcionalmente equivalentes, composiÇÕes farmacÊuticas e usos dos mesmos
RS56130B1 (sr) Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe
JP2012529444A (ja) ペプチドギャップ結合調節因子として作用する化合物及びその使用
KR20080000554A (ko) 화학적으로 변형된 펩티드 유사체
US20110098218A1 (en) Modulators of stat3 signalling
JP4603364B2 (ja) ペプチドギャップ結合モジュレーター
CN102558357B (zh) 一种可以治疗心肌缺血再灌注损伤的p38α拮抗肽
Dhein Peptides acting at gap junctions
US20100298225A1 (en) Peptide gap junction modulators
JP7785292B2 (ja) 血管新生および血管機能を阻害するオリゴペプチド
CN110945014B (zh) 电压门控钙通道缺陷亚基α2δ及其应用
JP3922345B2 (ja) 生理活性ペプチド
JP2009522314A (ja) プロリンリッチペプチド、医薬組成物、１つ又は複数のペプチドの使用及び治療方法
US20090012005A1 (en) Use of an angiotensin IV antagonist to treat insulin resistance or cardiovascular risk related to metabolic syndrome
SEVERINI et al. Amphibian tachykinins
MXPA06007241A (es) Moduladores de union de espacio de isopeptidos.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150317